연구용제품시약 > Antibody
[BioXCell Korea] InVivoSIM anti-human PD-1 (Nivolumab Biosimilar)
바이오엑스셀코리아
BioXCell 은(www.bxcell.com) (www.bxcell.co.kr)
In Vivo용 Antibody를 1mg,5mg,25mg,50mg,100mg
용량으로 직접 제조하며, 합리적인 가격으로
공급하는 회사입니다.
▶약 300여종의 제품을 보유(Mouse, Human, Rat ..)
▶high quality
▶bulk quantity (milligram to gram)
▶low endotoxin levels
▶well suited for in-vivo preclinical studies.
BioXCell Biosimilars 신제품 "InVivoSIM™"
InVivoSIM anti-human PD-1
(Nivolumab Biosimilar)
Catalog # SIM0003
SIZE: 1mg,5mg,25mg,50mg,100mg
This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Nivolumab making it ideal for research use.
This Nivolumab biosimilar reacts with human PD-1 (programmed death-1) also known as CD279.
PD-1 is a 50-55 kDa cell surface receptor encoded by the Pdcd1 gene that belongs to the CD28 family of the Ig superfamily.
PD-1 is transiently expressed on CD4 and CD8 thymocytes as well as activated T and B lymphocytes and myeloid cells. PD-1 expression declines after successful elimination of antigen.
Additionally, Pdcd1 mRNA is expressed in developing B lymphocytes during the pro-B-cell stage. PD-1’s structure includes a ITIM (immunoreceptor tyrosine-based inhibitory motif) suggesting that PD-1 negatively regulates TCR signals. PD-1 signals via binding its two ligands, PD-L1 and PD-L2 both members of the B7 family. Upon ligand binding, PD-1 signaling inhibits T-cell activation, leading to reduced proliferation, cytokine production, and T-cell death.
Additionally, PD-1 is known to play key roles in peripheral tolerance and prevention of autoimmune disease. Induced PD-L1 expression is common in many tumors including squamous cell carcinoma, colon adenocarcinoma, and breast adenocarcinoma. PD-L1 overexpression results in increased resistance of tumor cells to CD8 T cell mediated lysis. PD-L1 overexpression results in increased resistance of tumor cells to CD8 T cell mediated lysis. In experimental models of melanoma, tumor growth can be transiently arrested via treatment with antibodies which block the interaction between PD-L1 and its receptor PD-1.
For these reasons anti-PD-1 mediated immunotherapies are currently being used as cancer treatments. Nivolumab binds to PD-1 on activated immune cells to selectively block the interaction of PD-1 with its ligands.
Isotype | human IgG4 |
Recommended Isotype Control(s) | InVivoMAb polyclonal human IgG |
Recommended Dilution Buffer | InVivoPure™ pH 7.0 Dilution Buffer |
Immunogen | Human PD-1 |
Reported Applications |
|
Formulation |
|
Endotoxin |
|
Aggregation |
|
Sterility | 0.2 μM filtered |
Production | Purified from cell culture supernatant |
Purification | Protein A |
Molecular Weight | 150 kDa |
Murine Pathogen Test Results |
|
Storage | The antibody solution should be stored at the stock concentration at 4°C. Do not freeze. |
매주 목요일 4시 발주 1-2주 소요
자세한 문의사항은 본사로 문의해 주시기 바랍니다.
(BioXCell Korea는 BioClone의 자회사 입니다)
바이오엑스셀 코리아 (www.bxcell.co.kr)
Tel : 02)2013-8240 Fax : 02)2013-8243
본 정보는 "바이오엑스셀코리아" (으)로 문의 바랍니다.